Berlex ABOVE Study Will Evaluate Switching Avonex MS Patients To Betaseron
• By Pharmaceutical Approvals Monthly
Berlex/Chiron’s ABOVE (Interferon beta-1a vs. Interferon beta-1b Observation of Efficacy) study will evaluate whether there is a benefit to switching relapsing-remitting MS patients from once-weekly treatment with Biogen’s Avonex to Berlex’ more frequently administered and higher-dose Betaseron.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
